Virus production for clinical gene therapy

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• Gene therapy is a rapidly advancing field for treating human diseases, with viral vectors being central to over 50% of clinical trials, particularly for cancer.
• Current viral vector production often relies on labor-intensive, small-scale methods, creating bottlenecks in clinical translation.
• The demand for high-quality, clinical-grade viral preparations necessitates the development of robust and cost-effective manufacturing strategies.

Purpose of the Study:

• To address the bottlenecks in viral vector production for gene therapy.
• To present scalable upstream and downstream processing strategies for viral vector manufacturing.
• To detail characterization techniques for ensuring the quality of viral vectors for clinical use.

Main Methods:

• Integration of upstream and downstream processing steps for virus production.
• Case study focusing on recombinant budded baculoviruses for gene therapy applications.
• Description of scalable manufacturing methods and essential quality assessment techniques.

Main Results:

• Demonstration of integrated and scalable methods for producing recombinant baculoviruses.
• Detailed explanation of mandatory characterization techniques for quality control.
• Streamlining viral vector development from bench-scale to clinical-grade production.

Conclusions:

• Scalable and efficient viral vector production is essential for the future of gene therapy.
• The presented strategies for recombinant baculovirus production offer a viable solution to current manufacturing challenges.
• Comprehensive quality assessment is critical for the successful clinical application of gene therapy vectors.